Migraine Headache Drugs Market Trends and Forecast (2021-2031)
The Migraine Headache Drugs Market is expected to register a CAGR of 8.4% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by By Type (Abortive Medicine, and Preventive Medicine). The report is segmented by Route of Administration (Oral, Injection, and Others). The report is segmented by Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Migraine Headache Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Migraine Headache Drugs Market Segmentation
Type- Abortive Medicine
- Preventive Medicine
- Oral
- Injection
- Others
- Hospital-based Pharmacies
- Retail Pharmacies
- Online Pharmacies
Strategic Insights
Migraine Headache Drugs Market Growth Drivers- Migraine disorder prevalence: Earned by strong worldwide prevalence principles, migraine headache drug industry is going north. Relatively, this condition is estimated to affect nearly about 12 percent of all individuals globally and has higher incidence rates, especially among women, aged between 18 and 44 years. There is an increasing number of migraine sufferers, which is hence driving treatment demand and fuelling the market for migraine drugs. The ratios of development of chronic migraine conditions are highly burdensome with regards to disability and contribute further to the upsurge demand of effective medications.
- Development of New Technologies in Medication: Praise to the continuous advances in pharmaceutical research which has developed drugs effectively for the treatment of migraine. The latest categories of drugs such as CGRP inhibitors have revolutionized the treatment process of migraine. Examples are Aimovig, Emgality, and Ajovy, having the same principle to block CGRP, a significant molecules in migraine pathophysiology. The new found treatment therapies have excited the market by adoption from regulatory bodies such as the FDA.
- Heightened Awareness and Diagnosis: There has been a growing spotlight on healthcare awareness, which has led to rising identification and diagnosis of migraine headaches. More people are seeking medical assistance and getting tested for migraines, hence the consequent rise in treatment needs. These improved diagnostic techniques and more informative awareness-raising campaigns about migraine triggers and symptoms have resulted in better access to care. Awareness is both realizing the early diagnosis of hitherto undiscovered patients as well as, which may lead to better outcome and increased market for drugs.
- Part for Preventative Treatment Shifts: The market for migraine medicines is now trending toward prevention as more healthcare professionals recognize the benefits of early intervention. The purpose of preventive medicines is to reduce how often, how severely, and how long migraines occur. The use of botulinum toxin injections, anti-CGRP antibodies, and beta-blockers for chronic migraine patients is on the rise in popularity as long-term alternatives. This shift toward preventive therapy is increasing the range available to patients-of-prescription patterns.
- Adoption of Personalized Medicine: They also affect innovations and marketing of migraine therapies. Drug companies are trying to find ways to personalize migraine therapies due to the increased knowledge of the bases of the disease in its genetic and biochemical aspects.
- Digital Health Technology Use: For example, the digital health approaches that touch every aspect of migraine treatment protocols include using apps, wearables, and telemedicine platforms for its patients to symptomatically track and manage their conditions. Some online devices give patients very high chances to monitor their triggers and medication use and have remote consultations with health care providers. The heuristic and Davis suggest that such technology may not be left out when the patient engages the program in an accessible manner because it complements the management of their own future migraine episodes.
- Pipeline for Innovative New Drugs in Development: The migraine headache drugs market will benefit from a healthy pipeline for new and innovative therapies. Drug manufacturers are still continuously pouring their investment in R&D for developing next-generation migraine therapies. These treatments target generally specific inhibition of mechanisms involved in migraine pathophysiology, for example, of neuroinflammatory processes. That pipeline of innovation promises to widen therapeutic options for patients and create growth opportunities for the market.
- Rise of OTC Migraine Medications: There is an increasing opportunity in over-the-counter migraine treatment. Awareness of migraines has risen, and many patients opt for self-medication instead of going to a professional clinic. There is an established niche market for effective OTC migraine drugs such as combination analgesics and anti-inflammatory medications. Companies can extend their portfolios in this OTC segment further, making migraine relief available to a wider population, including those who cannot reach their healthcare professionals immediately.
- Collaborations and Strategic Partnerships: Strategic collaboration or partnership arrangement among pharmaceutical companies, biotechnology companies, and providers will provide the best advertisements for growth in migraine headache drugs. The combined resource will enable the huge companies to provide the research, development, and marketing efforts in introducing new therapies targeting existing migraine pathology. The relationship may lead to co-development of drugs with either or both parties able to market the individual product or combination therapy.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Migraine Headache Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Migraine Headache Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Abortive Medicine segment, by type, dominated the market in 2023.
Players operating in the market are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc, Impax Laboratories, Johnson and Johnson, Merck and Co., Pfizer Inc.
North America region dominated the Migraine Headache Drugs market in 2023.
Pipeline for Innovative New Drugs in Development act as a opportunity for growth of the market in forecast period.
The Migraine Headache Drugs Market is estimated to witness a CAGR of 8.4% from 2023 to 2031
The major factors driving the Migraine Headache Drugs market are:
1. Migraine disorder prevalence
2. Development of New Technologies in Medication
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Migraine Headache Drugs Market - By Type
1.3.2 Migraine Headache Drugs Market - By Route of Administration
1.3.3 Migraine Headache Drugs Market - By Distribution Channel
1.3.4 Migraine Headache Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MIGRAINE HEADACHE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MIGRAINE HEADACHE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MIGRAINE HEADACHE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. MIGRAINE HEADACHE DRUGS - GLOBAL MARKET OVERVIEW
6.2. MIGRAINE HEADACHE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. MIGRAINE HEADACHE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ABORTIVE MEDICINE
7.3.1. Overview
7.3.2. Abortive Medicine Market Forecast and Analysis
7.3.3. Triptans (Serotonin Receptor Agonists) Market
7.3.3.1. Overview
7.3.3.2. Triptans (Serotonin Receptor Agonists) Market Forecast and Analysis
7.3.4. Ergotamine Derivative Market
7.3.4.1. Overview
7.3.4.2. Ergotamine Derivative Market Forecast and Analysis
7.3.5. Others Market
7.3.5.1. Overview
7.3.5.2. Others Market Forecast and Analysis
7.4. PREVENTIVE MEDICINE
7.4.1. Overview
7.4.2. Preventive Medicine Market Forecast and Analysis
7.4.3. Anticonvulsant Market
7.4.3.1. Overview
7.4.3.2. Anticonvulsant Market Forecast and Analysis
7.4.4. Antidepressant Market
7.4.4.1. Overview
7.4.4.2. Antidepressant Market Forecast and Analysis
7.4.5. Beta Blocker Market
7.4.5.1. Overview
7.4.5.2. Beta Blocker Market Forecast and Analysis
7.4.6. Others Market
7.4.6.1. Overview
7.4.6.2. Others Market Forecast and Analysis
8. MIGRAINE HEADACHE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INJECTION
8.4.1. Overview
8.4.2. Injection Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. MIGRAINE HEADACHE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL-BASED PHARMACIES
9.3.1. Overview
9.3.2. Hospital-based Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. MIGRAINE HEADACHE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Migraine Headache Drugs Market Overview
10.1.2 North America Migraine Headache Drugs Market Forecasts and Analysis
10.1.3 North America Migraine Headache Drugs Market Forecasts and Analysis - By Type
10.1.4 North America Migraine Headache Drugs Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Migraine Headache Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Migraine Headache Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Migraine Headache Drugs Market
10.1.6.1.1 United States Migraine Headache Drugs Market by Type
10.1.6.1.2 United States Migraine Headache Drugs Market by Route of Administration
10.1.6.1.3 United States Migraine Headache Drugs Market by Distribution Channel
10.1.6.2 Canada Migraine Headache Drugs Market
10.1.6.2.1 Canada Migraine Headache Drugs Market by Type
10.1.6.2.2 Canada Migraine Headache Drugs Market by Route of Administration
10.1.6.2.3 Canada Migraine Headache Drugs Market by Distribution Channel
10.1.6.3 Mexico Migraine Headache Drugs Market
10.1.6.3.1 Mexico Migraine Headache Drugs Market by Type
10.1.6.3.2 Mexico Migraine Headache Drugs Market by Route of Administration
10.1.6.3.3 Mexico Migraine Headache Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Migraine Headache Drugs Market Overview
10.2.2 Europe Migraine Headache Drugs Market Forecasts and Analysis
10.2.3 Europe Migraine Headache Drugs Market Forecasts and Analysis - By Type
10.2.4 Europe Migraine Headache Drugs Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Migraine Headache Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Migraine Headache Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Migraine Headache Drugs Market
10.2.6.1.1 Germany Migraine Headache Drugs Market by Type
10.2.6.1.2 Germany Migraine Headache Drugs Market by Route of Administration
10.2.6.1.3 Germany Migraine Headache Drugs Market by Distribution Channel
10.2.6.2 France Migraine Headache Drugs Market
10.2.6.2.1 France Migraine Headache Drugs Market by Type
10.2.6.2.2 France Migraine Headache Drugs Market by Route of Administration
10.2.6.2.3 France Migraine Headache Drugs Market by Distribution Channel
10.2.6.3 Italy Migraine Headache Drugs Market
10.2.6.3.1 Italy Migraine Headache Drugs Market by Type
10.2.6.3.2 Italy Migraine Headache Drugs Market by Route of Administration
10.2.6.3.3 Italy Migraine Headache Drugs Market by Distribution Channel
10.2.6.4 Spain Migraine Headache Drugs Market
10.2.6.4.1 Spain Migraine Headache Drugs Market by Type
10.2.6.4.2 Spain Migraine Headache Drugs Market by Route of Administration
10.2.6.4.3 Spain Migraine Headache Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Migraine Headache Drugs Market
10.2.6.5.1 United Kingdom Migraine Headache Drugs Market by Type
10.2.6.5.2 United Kingdom Migraine Headache Drugs Market by Route of Administration
10.2.6.5.3 United Kingdom Migraine Headache Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Migraine Headache Drugs Market
10.2.6.6.1 Rest of Europe Migraine Headache Drugs Market by Type
10.2.6.6.2 Rest of Europe Migraine Headache Drugs Market by Route of Administration
10.2.6.6.3 Rest of Europe Migraine Headache Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Migraine Headache Drugs Market Overview
10.3.2 Asia-Pacific Migraine Headache Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Migraine Headache Drugs Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Migraine Headache Drugs Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Migraine Headache Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Migraine Headache Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Migraine Headache Drugs Market
10.3.6.1.1 Australia Migraine Headache Drugs Market by Type
10.3.6.1.2 Australia Migraine Headache Drugs Market by Route of Administration
10.3.6.1.3 Australia Migraine Headache Drugs Market by Distribution Channel
10.3.6.2 China Migraine Headache Drugs Market
10.3.6.2.1 China Migraine Headache Drugs Market by Type
10.3.6.2.2 China Migraine Headache Drugs Market by Route of Administration
10.3.6.2.3 China Migraine Headache Drugs Market by Distribution Channel
10.3.6.3 India Migraine Headache Drugs Market
10.3.6.3.1 India Migraine Headache Drugs Market by Type
10.3.6.3.2 India Migraine Headache Drugs Market by Route of Administration
10.3.6.3.3 India Migraine Headache Drugs Market by Distribution Channel
10.3.6.4 Japan Migraine Headache Drugs Market
10.3.6.4.1 Japan Migraine Headache Drugs Market by Type
10.3.6.4.2 Japan Migraine Headache Drugs Market by Route of Administration
10.3.6.4.3 Japan Migraine Headache Drugs Market by Distribution Channel
10.3.6.5 South Korea Migraine Headache Drugs Market
10.3.6.5.1 South Korea Migraine Headache Drugs Market by Type
10.3.6.5.2 South Korea Migraine Headache Drugs Market by Route of Administration
10.3.6.5.3 South Korea Migraine Headache Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Migraine Headache Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Migraine Headache Drugs Market by Type
10.3.6.6.2 Rest of Asia-Pacific Migraine Headache Drugs Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Migraine Headache Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Migraine Headache Drugs Market Overview
10.4.2 Middle East and Africa Migraine Headache Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Migraine Headache Drugs Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Migraine Headache Drugs Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Migraine Headache Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Migraine Headache Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Migraine Headache Drugs Market
10.4.6.1.1 South Africa Migraine Headache Drugs Market by Type
10.4.6.1.2 South Africa Migraine Headache Drugs Market by Route of Administration
10.4.6.1.3 South Africa Migraine Headache Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Migraine Headache Drugs Market
10.4.6.2.1 Saudi Arabia Migraine Headache Drugs Market by Type
10.4.6.2.2 Saudi Arabia Migraine Headache Drugs Market by Route of Administration
10.4.6.2.3 Saudi Arabia Migraine Headache Drugs Market by Distribution Channel
10.4.6.3 U.A.E Migraine Headache Drugs Market
10.4.6.3.1 U.A.E Migraine Headache Drugs Market by Type
10.4.6.3.2 U.A.E Migraine Headache Drugs Market by Route of Administration
10.4.6.3.3 U.A.E Migraine Headache Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Migraine Headache Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Migraine Headache Drugs Market by Type
10.4.6.4.2 Rest of Middle East and Africa Migraine Headache Drugs Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Migraine Headache Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Migraine Headache Drugs Market Overview
10.5.2 South and Central America Migraine Headache Drugs Market Forecasts and Analysis
10.5.3 South and Central America Migraine Headache Drugs Market Forecasts and Analysis - By Type
10.5.4 South and Central America Migraine Headache Drugs Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Migraine Headache Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Migraine Headache Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Migraine Headache Drugs Market
10.5.6.1.1 Brazil Migraine Headache Drugs Market by Type
10.5.6.1.2 Brazil Migraine Headache Drugs Market by Route of Administration
10.5.6.1.3 Brazil Migraine Headache Drugs Market by Distribution Channel
10.5.6.2 Argentina Migraine Headache Drugs Market
10.5.6.2.1 Argentina Migraine Headache Drugs Market by Type
10.5.6.2.2 Argentina Migraine Headache Drugs Market by Route of Administration
10.5.6.2.3 Argentina Migraine Headache Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Migraine Headache Drugs Market
10.5.6.3.1 Rest of South and Central America Migraine Headache Drugs Market by Type
10.5.6.3.2 Rest of South and Central America Migraine Headache Drugs Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Migraine Headache Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL MIGRAINE HEADACHE DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. MIGRAINE HEADACHE DRUGS MARKET, KEY COMPANY PROFILES
13.1. ABBOTT LABORATORIES
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ALLERGAN PLC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ASTRAZENECA
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. EISAI CO., LTD.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ENDO INTERNATIONAL PLC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. GLAXOSMITHKLINE PLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. IMPAX LABORATORIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. JOHNSON AND JOHNSON
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. MERCK AND CO.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. PFIZER INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Abbott Laboratories
2. Allergan Plc.
3. AstraZeneca
4. Eisai Co., Ltd.
5. Endo International Plc.
6. GlaxoSmithKline Plc
7. Impax Laboratories
8. Johnson and Johnson
9. Merck and Co.
10. Pfizer Inc.
11. Amgen
12. Teva Pharma
13. Eli Lilly
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For